CONSORZIO ONCOTECH
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
47
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (32 trials with phase data)• Click on a phase to view related trials
"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"
- Conditions
- Breast Cancer
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 1000
- Registration Number
- NCT06871501
- Locations
- 🇮🇹
A.O. San Giuseppe Moscati, Avellino, AV, Italy
🇮🇹Ospedale Papa Giovanni XXIII, Bergamo, BG, Italy
🇮🇹Policlinico S. Orsola-Malpighi, Bologna, BO, Italy
Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario
- Conditions
- Ovarian Cancer
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 300
- Registration Number
- NCT06836219
- Locations
- 🇮🇹
Istituto Tumori "Giovanni Paolo II" I.R.C.C.S., Bari, BA, Italy
🇮🇹Azienda Ospedaliero Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, BO, Italy
🇮🇹Azienda Ospedaliera S.Croce e Carle Cuneo, Cuneo, CN, Italy
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 122
- Registration Number
- NCT05833919
- Locations
- 🇮🇹
Fondazione Poliambulanza, Istituto Ospedaliero, Brescia, Italy
🇮🇹A.R.N.A.S. Garibaldi - P.O. Nesima, Catania, Italy
🇮🇹A.O. Pugliese-Ciaccio, Catanzaro, Italy
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 118
- Registration Number
- NCT05817903
- Locations
- 🇮🇹
ASST degli Spedali Civili di Brescia, Brescia, Italy
🇮🇹Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Italy
🇮🇹Azienda Ospedaliera per l'emergenza Cannizzaro, Catania, Italy
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
- Conditions
- Breast Cancer
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 300
- Registration Number
- NCT05754502
- Locations
- 🇮🇹
Nuovo ospedale di Prato - S. Stefano, Prato, Firenze, Italy
🇮🇹A.O.U. Ospedali Riuniti Umberto I, Ancona, Italy
🇮🇹IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
- Prev
- 1
- 2
- 3
- 4
- 5
- Next